Fig 2.TIF (871.61 kB)
Effect of ipragliflozin on liver gene expression in HFD-fed WT mice.
figure
posted on 2016-03-15, 00:23 authored by Chikara Komiya, Kyoichiro Tsuchiya, Kumiko Shiba, Yasutaka Miyachi, Shunsaku Furuke, Noriko Shimazu, Shinobu Yamaguchi, Kazuo Kanno, Yoshihiro OgawaGene expression levels in the liver associated with (A) lipogenesis, β-oxidation, gluconeogenesis, and (B) inflammation after 4 weeks of the vehicle or ipragliflozin treatment. # p < 0.05, ## p < 0.01 vs SD/Veh; * p < 0.05, ** p < 0.01 vs HFD/Veh. n = 6–8.
History
Usage metrics
Categories
Keywords
epididymalType 2 Diabetic Patients Irrespectiveipragliflozin ameliorates obesity-associated inflammationT 2DM hepatic steatosisaccumulationSGLT 2 inhibitorsattenuating body weight reductionBody Weight Reduction Type 2 diabetes mellitusinsulin resistancebody weightSGLT 2 inhibitor ipragliflozinNAFLDincrease energy intakeT 2DMbody weight reductionSodium-glucose cotransporter 2
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC